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The requirement for the maintenance of telomeres by telomerase by most cancer cells for continued proliferation is a target in
anticancer strategies. Tankyrases are poly(ADP-ribose) polymerases that enhance telomerase access to telomeres. Tankyrase 1
modulates telomerase inhibition in human cancer cells and is reviewed in this report as a potential telomere-directed anticancer
target.
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Telomeres, the protective DNA–protein complexes at eukaryotic
chromosome ends, are distinguished from DNA double-strand
breaks, which would otherwise cause nonhomologous end joining
or homologous recombination. DNA replication machinery cannot
replicate the very ends of chromosomal DNA, known as the end
replication problem, and this would result in the gradual loss of
telomeres after each round of DNA replication, unless new
telomeric DNA was synthesized by telomerase. The level of
telomerase activity in most human somatic cells is so weak that
telomere attrition is unavoidable. Critically shortened telomeres
are recognized as damaged DNA (d’Adda di Fagagna et al, 2003),
and this leads to replicative cell senescence. As a result, telomeres
are often referred to as a ‘mitotic clock’ that predetermines the
replicative capacity of mortal cells. In contrast with human somatic
cells, up to 90% of all human cancer cells have a high level of
telomerase activity that maintains telomere length (Kim et al,
1994).
Telomerase consists of a ubiquitously expressed RNA template,
TR (or TERC), and a catalytic subunit, TERT, the expression of
which is the limiting factor for the enzyme’s activity. TERT
expression correlates positively with cellular immortalization and
carcinogenesis. Introduction of dominant-negative TERT mutants
into cancer cells shortens their telomeres and induces subsequent
apoptosis (Hahn et al, 1999; Zhang et al, 1999). The activation of
telomerase by most cancer cells effectively bypasses replicative
senescence. Accordingly, telomerase has been promoted as a
potential target in anticancer strategies, and various telomerase
inhibitors have been reported (Seimiya et al, 2002 and references
therein). This minireview describes some potential problems with
telomerase inhibitors and introduces the telomeric poly(ADP-
ribose) polymerases (PARP), tankyrase 1 and 2 (Figure 1), as the
second potential target for telomere-directed molecular cancer
therapeutics.
TELOMERE ELONGATION BY TANKYRASE 1
In telomerase-positive cells, average telomere length is stabilized
by a ‘protein-counting’ mechanism, in which a series of telomere-
associated proteins negatively regulate telomere elongation by
telomerase (reviewed in Smogorzewska and de Lange, 2004).
Longer telomeres have greater numbers of TRF1, a double-
stranded telomeric repeat binding protein. In conjunction with the
downstream TIN2-TPP1-POT1 telomere-associated complex, TRF1
blocks access of telomerase to telomeres (Figure 2).
Tankyrase 1 (TRF1-interacting ankyrin-related ADP-ribose
polymerase 1) was originally identified as a TRF1-binding protein
by using a yeast two-hybrid screen (Smith et al, 1998). This
140-kDa protein consists of four characteristic domains (Figure 1):
the N-terminus is known as the HPS domain, containing homo-
polymeric runs of histidine, proline, and serine. The functional
significance of the HPS domain is unknown. Tankyrase 1 is also
comprised of an ANK domain placing the protein within the ANK
family of proteins. As in the original ankyrins, the tankyrase 1
ANK domain is composed of a long stretch of 24 ANK repeats,
providing a platform for protein–protein interactions. Unlike the
ANK of ankyrins, the ANK domain of tankyrase 1 is further
divided into five well-conserved subdomains (Seimiya and Smith,
2002; De Rycker et al, 2003). Each subdomain, designated as ARC
(ANK repeat cluster) I–V, works as an independent TRF1-binding
site. TRF1 recognition by the most C-terminal subdomain ARC V
is the most important for the telomeric function of tankyrase 1
(Seimiya and Smith, 2002; Seimiya et al, 2004). The sterile alpha
motif (SAM) domain, adjacent to the ARC V domain, contributes
to multimerization of tankyrase 1 (De Rycker et al, 2003; De Rycker
and Price, 2004). The most striking feature of tankyrase 1 is the C-
terminal PARP domain, which catalyses poly(ADP-ribosyl)ation of
acceptor proteins using NAD as a substrate. This post-translational
modification provides significant negative charges to the acceptor
proteins and often disrupts interactions between the acceptor
proteins and the DNA. In general, poly(ADP-ribosyl)ation is
involved in various physiological events, such as DNA replication,
DNA repair, gene expression, chromatin decondensation, malignant
transformation, cellular differentiation, and apoptosis.
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www.bjcancer.comTankyrase 1 recognizes TRF1 via the ARC subdomains within
the ANK domain and is localized at the telomeres (Smith et al,
1998; Cook et al, 2002; Seimiya and Smith, 2002). TRF1 is
poly(ADP-ribosyl)ated by tankyrase 1, and this modification
blocks the ability of TRF1 to bind telomeric DNA in vitro (Smith
et al, 1998). In intact human cells, tankyrase 1 releases TRF1 from
telomeres in a PARP activity-dependent manner (Smith and de
Lange, 1999; Cook et al, 2002). Released TRF1 is rapidly
ubiquitinated and subjected to proteasomal degradation (Chang
et al, 2003), thereby explaining the striking linkage between
poly(ADP-ribosyl)ation and protein degradation. Consistent with
these observations, telomere elongation is induced by the over-
expression of exogenous tankyrase 1 in the nucleus of telomerase-
positive cells (Smith and de Lange, 2000). Also confirming the
above findings, tankyrase 1-mediated telomere elongation is not
observed in the absence of telomerase activity (Cook et al, 2002;
Chang et al, 2003; Seimiya et al, 2005). Thus, by enhancing
telomere access to telomerase, tankyrase 1 works as a positive
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Figure 1 Structures of tankyrase 1 and tankyrase 2. HPS, homopolymeric runs of His, Pro, and Ser, without known functions; ANK, ankyrin domain,
consisting of 24 ANK repeats; SAM, multimerization domain homologous to the sterile alpha motif; PARP, PARP catalytic domain that adds ADP-ribose
chains onto acceptor proteins. The ANK domain is further divided into five well-conserved ANK repeat clusters (ARC), each of which contributes to ligand
binding. Bridges above two adjacent ANK repeats indicate the presence of a conserved histidine contributing to inter-repeat stabilization.
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Figure 2 Telomere elongation by tankyrase 1 and impact on telomerase inhibitors. For telomere elongation, active telomerase needs to gain access to the
telomeric 30-overhang. The TRF1-TIN2-TPP1-POT1 telomeric protein complex limits telomerase access, whereas tankyrase 1 removes the telomeric
protein complex by poly(ADP-ribosyl)ating TRF1. Either telomere shortening or tankyrase 1 upregulation, each of which decreases the TRF1-TIN2-TPP1-
POT1 loading on a chromosome end, attenuates the impact of telomerase inhibitors by allowing access of residual telomerase activity. Conversely, blockade
of tankyrase 1 enhances the effect of telomerase inhibitors. The relative importance of tankyrase 1 vs tankyrase 2 inhibition remains unclear.
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supposition that the action of telomerase at the telomere may be
regulated by inhibitors of telomerase and also by molecules that
regulate tankyrase 1, and hence telomere structure and telomerase
access to the telomere (see below).
Tankyrase 2 is a closely related homologue of tankyrase 1 (see
below). Tankyrase 1 forms a ternary complex with TRF1 and
another TRF1-binding protein, TIN2. In this complex, poly(ADP-
ribosyl)ation of TRF1 is prevented by TIN2 (Ye and de Lange,
2004). The mechanisms underlying tankyrase activation or in-
hibition are unknown. It is known that tankyrase 1 is not activated
by damaged DNA, which is an activator of PARP-1, the most
abundant member among the PARP family (Cook et al, 2002).
TANKYRASES AS TARGETS FOR CANCER THERAPY
As described above, telomere maintenance by telomerase is the
Achilles’ heel of infinite growth for most cancer cells (Hahn et al,
1999; Zhang et al, 1999). Continuous treatment of cancer cells with
telomerase inhibitors shortens telomeres and eventually induces
cellular senescence and/or apoptosis (Seimiya et al, 2002 and
references therein). Thus, according to this simple scenario,
telomerase inhibitors have the potential to benefit cancer patients
in the future.
A potential disadvantage is that telomere shortening depends on
the repetitive occurrence of the DNA end replication problem
resulting from cell division. For this reason, it is essential that
telomerase inhibitors are not cytotoxic. Furthermore, as telomere
loss is a gradual process there is a lag between the time telomerase
is inhibited and the time telomeres shorten sufficiently to disrupt
the capping function. This would necessitate long treatment
schedules that may lead to acquired drug resistance both in the
cell and throughout the body. In general, longer telomeres provide
more binding sites for TRF1, which blocks telomere access to
telomerase. Accordingly, telomere shortening per se compromises
the effect of telomerase inhibitors since shorter telomeres have
fewer TRF1 molecules and therefore allow easier access to residual
telomerase activity (Seimiya et al, 2005). Thus, the rate of telomere
shortening per cell division decreases with telomere shortening
itself. This phenomenon results from the incomplete shutdown of
telomerase activity by telomerase inhibitors. A better therapeutic
outcome may result from increasing the efficiency of telomere
shortening to hasten the telomere crisis.
Telomere accessibility is also a potential target for telomerase
inhibition. Inhibition of tankyrases, that enhance telomerase
access to telomeres, may indirectly induce cancer cell senescence
by abrogating telomerase activity. Support for this rational is
provided by the finding that tankyrase 1 confers resistance to
telomerase inhibitors (Figure 2). In these experiments cells
overexpressing tankyrase 1, which removes TRF1 from telomere
DNA, have unchanged telomere length following treatment with
the telomerase inhibitor, MST-312. This drug resistance is reversed
by several known PARP inhibitors, such as 3-aminobenzamide
(3AB) and PJ-34, which are able to block tankyrase 1 PARP activity
(Seimiya et al, 2005). Even in cells that do not overexpress
exogenous tankyrase 1 (but do express endogenous tankyrase 1),
these PARP inhibitors enhance the rate of telomere shortening by
means of a telomerase inhibitor, MST-312 (Seimiya et al, 2002),
and induce earlier cell crisis. These PARP inhibitors do not directly
inhibit telomerase activity but lead to telomere shortening, to a
small extent, presumably by reducing telomere access to
telomerase. Furthermore, MST-312 resistance caused by telomere
shortening per se is reversed by 3AB. By comparison, 3AB has no
effect on telomere length in telomerase-independent ALT (alter-
native lengthening of telomeres)-type cells, which maintain their
telomere length by DNA recombination. Also, telomere shortening
caused by an inherent end replication problem in normal
fibroblasts is not accelerated by 3AB (Seimiya et al, 2005). Thus,
it is expected that the effect of such PARP inhibitors on telomere
length is selective to telomerase-positive cells. These observations
provide support for tankyrase 1 as a suitable target for telomere-
directed cancer therapy. Pathologically, tankyrase 1 gene expres-
sion is elevated in some tumours but not in others (Gelmini et al,
2004 and references in therein).
Another avenue for telomerase inhibition has recently emerged.
Li et al (2004) reported that knockdown of the hTR telomerase
RNA component by RNA interference (RNAi) induces a rapid
antiproliferative effect on telomerase-positive cancer cells. Un-
expectedly, this effect occurs without telomere attrition and is
thereby independent of the initial telomere length of the target
cells. These observations suggest that telomerase inhibition has
bimodal effects on human cancer cells and that telomerase
inhibitors may exert a more acute therapeutic effect than expected.
OTHER FACES OF TANKYRASES
Multiple functions of tankyrases in accordance with a variety of
binding partners pose the next challenging question about
potential side effects of tankyrase-directed cancer therapy.
Tankyrase 1 is also present at nontelomeric loci, including mitotic
centrosomes, nuclear pore complexes, and Golgi apparatus (Smith
and de Lange, 1999; Chi and Lodish, 2000). Furthermore, tankyrase
1 has a closely related homologue, tankyrase 2 that unlike tank-
yrase 1 lacks HPS domain. Tankyrase 1 is relatively abundant in
reproductive tissues (i.e. testis and ovary), whereas the expression
of tankyrase 2 is ubiquitous (Smith et al, 1998; Kaminker et al,
2001; Lyons et al, 2001; Cook et al, 2002). The functional difference
and redundancy between the two proteins remain unknown.
Nontelomeric tankyrase 1/2-binding partners include insulin-
responsive aminopeptidase (IRAP) (Chi and Lodish, 2000), the
Grb14 signalling adaptor protein (Lyons et al, 2001), the 182kDa
tankyrase-binding protein (TAB182) (Seimiya and Smith, 2002),
the nuclear/mitotic apparatus protein (NuMA) (Sbodio and Chi,
2002; Chang et al, 2005b), the Mcl-1 apoptotic regulator (Bae et al,
2003), and the Epstein–Barr virus nuclear antigen-1 (EBNA-1)
(Deng et al, 2005). So far, TRF1, IRAP, TAB182, NuMA, EBNA-1
and tankyrase 1 and 2 are poly(ADP-ribosyl)ated by tankyrases.
The Golgi tankyrase 1 colocalizes with the glucose transporter
GLUT4 vesicles where tankyrase 1 is associated with IRAP (Chi
and Lodish, 2000). In insulin-stimulated adipocytes, tankyrase 1 is
phosphorylated at serine residues by the mitogen-activated protein
kinase pathway. Phosphorylation of tankyrase 1 results in
upregulation of its intrinsic PARP activity (Chi and Lodish,
2000). Although the function of tankyrase 1 at the Golgi is unclear,
the artificial formation of tankyrase 1-containing vesicles disrupts
Golgi structure and inhibits apical secretion (De Rycker and Price,
2004).
During mitosis, tankyrase 1 is concentrated around the
pericentriolar matrices (Smith and de Lange, 1999) in a NuMA-
dependent manner (Chang et al, 2005b). NuMA plays an essential
role in organizing microtubules at the spindle poles. As NuMA is
poly(ADP-ribosyl)ated by tankyrase 1 during mitosis (Chang et al,
2005b), it is possible that tankyrase 1 regulates NuMA’s function at
the spindle poles. Interestingly, poly(ADP-ribosyl)ation is required
for spindle assembly and structure (Chang et al, 2004), and
tankyrase 1 is a key player in these processes (Chang et al, 2005a).
Another fraction of tankyrase 1 remains at telomeres during
mitosis (Smith et al, 1998) and is thought to play a role in sister
chromatid resolution at telomeres. Support for this role of
tankyrase 1 was provided by the metaphase arrest of cell division
in tankyrase 1 knockdown experiments in which pairs of sister
chromatids remain associated only at telomeres (Dynek and Smith,
2004). Recently, metaphase arrest by tankyrase 1 knockdown has
been reported by another group, who shows intact sister
Tankyrases in cancer therapy
H Seimiya
343
British Journal of Cancer (2006) 94(3), 341–345 & 2006 Cancer Research UKchromatid cohesion, instead of telomeric cohesion, in tankyrase 1
knockdown cells (Chang et al, 2005a).
The protein structure of tankyrases suggests they act as
scaffolding molecules. First, each of the five ARC subdomains
works as an independent recognition site for tankyrase-binding
proteins. This suggests that even a single tankyrase molecule can
interact with multiple binding partners (Seimiya and Smith, 2002;
Seimiya et al, 2004). Secondly, the SAM domain multimerizes
tankyrases in an auto-poly(ADP-ribosyl)ation-sensitive manner.
This multimerization presumably leads to assembly of a larger
molecular lattice (De Rycker et al, 2003; De Rycker and Price,
2004) and may explain why tankyrase-binding proteins often
localize to higher order intracellular structures, such as telomeres
(TRF1), Golgi (IRAP), spindle poles (NuMA), and cortical actin
(TAB182).
It is intriguing that murine TRF1 lacks the tankyrase recognition
consensus site, RXX(P/A)DG, suggesting that the telomeric
function of tankyrases is not conserved in mice (Sbodio and Chi,
2002). Other reported functions of tankyrases include involvement
in apoptosis (Bae et al, 2003) and episomal regulation of Epstein–
Barr virus OriP (origin of plasmid) (Deng et al, 2005). Taken
together, these observations suggest an expanding network of
tankyrase-mediated biological processes.
CONCLUDING REMARKS
The pharmacological targeting of tankyrase 1 is a potentially
significant anticancer strategy if used in conjunction with
inhibitors of telomerase. This trend would further promote
development not only of telomerase inhibitors but also of PARP
inhibitors. In fact, recently, PARP inhibitors have been shown to
be powerful against DNA repair-deficient tumours with the
advantage of low cytotoxicity (Bryant et al, 2005; Farmer et al,
2005). PARP inhibitors are also implicated in other PARP-related
diseases, such as stroke, myocardial ischaemia, diabetes, and
central nervous system injury. Tankyrases also have multiple
functions and we have to consider the potential side effects
resulting from their inhibition. It is possible that the function of
tankyrase 1 in mitosis (Dynek and Smith, 2004; Chang et al, 2005a)
is less affected by PARP inhibitors than its function in
maintenance of telomere length as mitosis is unaffected in PARP
inhibitor-treated cells (Seimiya et al, 2005). At the physiological
level, mechanisms for tankyrase regulation and the functional
redundancy between tankyrase 1 and 2 are largely unknown.
Future experiments in tankyrase 1 and 2 knockout animals may
elucidate the mechanisms underlying the many functions of the
tankyrase enzymes.
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